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The principle steroidal androgens are testosterone and its metabolite
5α-dihydrotestosterone (DHT), which is converted from testosterone by the enzyme
5α-reductase. Through the classic pathway with androgens crossing the plasma mem-
brane and binding to the androgen receptor (AR) or via mechanisms independent of
the ligand-dependent transactivation function of nuclear receptors, testosterone induces
genomic and non-genomic effects respectively. AR is widely distributed in several tissues,
including vascular endothelial and smooth muscle cells. Androgens are essential for many
developmental and physiological processes, especially in male reproductive tissues. It
is now clear that androgens have multiple actions besides sex differentiation and sexual
maturation and that many physiological systems are influenced by androgens, including
regulation of cardiovascular function [nitric oxide (NO) release, Ca2+ mobilization, vascular
apoptosis, hypertrophy, calcification, senescence and reactive oxygen species (ROS)
generation]. This review focuses on evidence indicating that interplay between genomic
and non-genomic actions of testosterone may influence cardiovascular function.
Introduction
Steroid hormones, including androgens, are involved in many developmental and physiological pro-
cesses [1–4]. Classically androgens mediate their effects via binding to the androgen receptor (AR), a
ligand-dependent transcription factor and a member of the nuclear receptor gene superfamily [5,6]. Ad-
ditionally, androgens can activate signalling pathways via non-DNA binding-dependent actions [7,8]. AR
is expressed inmany tissues, with the highest concentration being in themale reproductive organs [9]. The
AR has three functional domains: exon 1 encodes the N-terminal transactivation domain (NBD), exons
2 and 3 encode the DNA-binding domain (DBD) and exons 4–8 encode the C-terminus ligand-binding
domain (LBD) [10,11].
The AR is expressed in many cells of the cardiovascular system including cardiomyocytes [12], en-
dothelial cells [13], vascular smooth muscle cells (VSMCs) [14], fibroblasts [15], macrophages [16]
and platelets [17]. There are sex differences in AR expression; males have significantly higher levels of
AR mRNA than females [18]. In addition, males demonstrate greater AR activation with endogenous
testosterone, and prolonged exposure to endogenous testosterone leads to up-regulation of AR [19].
Testosterone is the principal male steroid hormone from the androgen family. Approximately 95% of
endogenous testosterone is produced by the testes and it is secreted by the Leydig cells [20]. Small amounts
of testosterone are also secreted by the zona reticularis of the adrenal glands [21]. The physiological levels
of testosterone in men range from 10 to 30 nM with lower levels found in women (0.6–2.5 nM) [22].
Testosterone is synthesized from cholesterol and stored in lipid droplets through a series of reactions that
occur in mitochondria and microsomes (smooth endoplasmic reticulum and surrounding cytoplasm).
The first step of steroidogenesis is a transfer of cholesterol to the internal mitochondrial membrane with
subsequent bioconversion in pregnenolone by the enzyme cytochrome P450 SCC [23]. Pregnenolone is
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then transferred to the endoplasmic reticulumwhere it is converted into testosterone through a series of enzymatic re-
actions via generation of 17α-hydroxypregnenolone and subsequent formation of dehydroepiandrosterone (DHEA)
or via 17α-hydroxyprogesterone. Approximately 7% of testosterone can then be converted to a more potent meta-
bolite, dihydrotestosterone (DHT) via 5α-reductase, and small amounts (approximately 0.5%) to oestrogen via P450
aromatase [24–26].
Testosterone binds with high affinity to the cytosolic or membrane AR and then regulates male sex development
and maturation [25] as well as having crucial extra-gonadal effects including regulation of apoptosis via cleavage of
procaspase 8 in VSMC [14], regulation of leucocyte migration and reactive oxygen species (ROS) generation [27],
control of the nitric oxide (NO)–cGMP pathway [2] and improvement of insulin sensitivity [28]. Testosterone has
also been used clinically in erectile dysfunction (ED), infertility, osteoporosis, to promote bone marrow stimulation
and to stimulate penile enlargement and height growth [29,30]. In athletes, testosterone has been shown to enhance
performance via muscle development, improved strength and endurance [31]. Moreover, androgens have been im-
plicated to play a role in pathological processes when dysregulated [32].
Testosterone has been associated with cardiovascular pathology as evidenced by a higher male susceptibility to
cardiovascular disease [19,33]. However, there is increasing evidence that low endogenous levels of testosterone may
also be associated with cardiac dysfunction [34–36]. A reduction in total testosterone of 2.18 SD is associated with
a 25% increased risk of cardiovascular mortality [37]. To date, the role of androgens in cardiovascular health and
disease remains controversial.
AR is a single copy gene found on the X chromosome at Xq11-12 and mutations and polymorphisms in it are
thought to be inversely proportional to the transcriptional response to testosterone [38]. To regulate target gene tran-
scription, testosterone and DHT can bind to the AR in a DNA binding-dependent manner leading to new protein
synthesis [25], or in a non-DNA binding-dependent manner that involves a rapid induction of secondary messengers
to initiate cellular events, such as protein phosphorylation [39]. DHT is more biologically active than testosterone,
which is associated with the 2-fold higher affinity for the AR and a reduction of 5-fold in the dissociation rate com-
pared with testosterone [40].
The classical DNA binding-dependent actions of the
androgens
In the basal state, without ligand binding, the AR is located primarily in the cytoplasm where it associates with
heat shock proteins (HSPs), which are thought to tether AR via cytoskeletal proteins and modulate AR conform-
ation in preparation for efficient ligand binding [41,42]. The classical AR signalling pathway commonly referred
to as ‘genomic’ or ‘canonical’ AR signalling involves androgens crossing the plasma membrane, entering the cyto-
plasm and binding to the AR, resulting in a dissociation of chaperone proteins, translocation of the complex to the
nucleus where it dimerizes and binds to androgen response element (ARE) to modulate gene transcription and sub-
sequently protein synthesis [40]. AR binding to specific ARE results in recruitment of histone acetyltransferase (HAT)
enzymes and a number of essential co-regulators [41]. This facilitates binding of TATA-binding protein (TBP) fol-
lowed by general transcription factors (GTF and RNA pol II) to begin transcription and to regulate the expression of
androgen-regulated genes [41,43].
Genomic action of the AR in vascular calciﬁcation
The relationship between testosterone and calcification, which is an important predictor of morbidity and mortality
from cardiovascular disease, has been explored [44]. There is significant sexual dimorphism in the development of
vascular calcification; males tend to have higher levels of calcium deposition, and this has been attributed as poten-
tially secondary to the effects of the AR [45]. Recently, it was demonstrated that higher expression of AR occurs in
calcified human aortic valve compared with controls. Treatment with androgens (testosterone or DHT) for 9 days
resulted in up-regulation of AR expression in WTmice and also induced calcification, as shown by elevated calcium
deposition and mRNA expression of Alpl, a marker of cellular mineralization, effects reduced in specific AR-ablated
VSMC with a concurrent reduction in the mRNA expression of the osteogenic marker Osterix [46]. Other studies
indicate the opposite, testosterone as an anti-calcification agent. Growth arrest-specific gene 6 (Gas6) is an important
molecule regulating calcification of VSMC [47]. Gas6 is considered a pro-survival agent that reduces apoptosis, an
essential process for VSMC calcification [48]. In VSMC, AR was found to directly bind to the ARE in the Gas6 pro-
moter region and to transactivate Gas6. This resulted in inhibition of inorganic phosphate (Pi)-induced calcification
of vascular cells. Restoration of Gas6 signalling induced by testosterone is mediated by phosphorylation of the phos-
phoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, and an increase in anti-apoptotic Bcl2 family proteins.
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This effect is blunted by AR antagonists [49] and provides a mechanism behind the possible cardioprotective action
of androgens, as suggested by the high levels of vascular calcification in men with hypogonadism [45]. Testosterone
also regulates VSMC senescence via Gas6 activation. Angiotensin II (Ang II)-induced down-regulation of Gas6 in
VSMC is restored by testosterone, which is followed by reduced expression and activity of MMP-2 and reduced Ang
II-induced collagen synthesis effects not observed in the presence of Gas6 blockers and Axl-Fc and PI3K inhibitors.
These results suggest a novel mechanism that involves Gas6/Axl and Akt in the protective effects of testosterone on
vascular ageing [50].
Genomic action of the AR in renal function, cardiac function and
vasodilation
Functionally, active AR is also thought to be integral to the maintenance of normal cardiac and renal function. Car-
diac and renal hypertrophy is common in Fabry disease, a condition caused by the deficiency of lysosomal enzyme
α-galactosidase A [51]. The α-galactosidase A knockout mice, a model of Fabry disease, demonstrate increased
mRNA and activity of AR in heart and kidneys, as indicated by increased expression of insulin-like growth factor 1,
an androgen regulated gene, and reduced expression of transforming growth factor-β1, which is negatively regulated
by AR. Castration and the consequent hypogonadism or AR-antagonism therapy results in a significant reduction in
Akt phosphorylation and an improved phenotype in the heart and kidneys of Fabry disease model mice [52]. Echo-
cardiography demonstrated improved heart-to-body weight ratios and left ventricle wall thickness and cardiac atrial
natriuretic peptide mRNA levels in castrated mice. Kidney weight also remained at WT level in these mice [52].
To explore the role of the AR in cardiac growth, Ikeda et al. used 25-week-old AR knockout (ARKO) mice and
age-matched wild-type male mice, which were treated with or without Ang II stimulation at a dose of 2mg/kg per
day for 2 weeks [53]. The importance of the AR in cardiac development and function is highlighted by the phen-
otype of AR knockout animals, as ARKO mice have a significant reduction in cardiac hypertrophy induced by
Ang II and heart-to-body weight ratio compared with WT, events associated with lower activation of extracellular
signal-regulated kinases (ERKs) 1/2 and ERK5. In addition, impairment of left ventricle function and cardiac fibrosis
induced by Ang II is reduced in ARKO mice [53].
Cross-talk between cytosolic and nuclear signalling pathways is involved in testosterone-induced cardiac hyper-
trophy. Glycogen synthase kinase 3 (GSK-3β) is considered an anti-hypertrophic factor in cardiac cells [54]. In car-
diomyocytes, treatment with testosterone leads to phosphorylation of GSK-3β inhibitory site (Ser9), an increase in
intracellular levels of calciumwith consequent activation of calcineurin and nuclear factor of activated T cells (NFAT)
and an increase in both cell size and [3H]-leucine incorporation, which suggest cardiomyocyte hypertrophy [55], sug-
gesting that GSK-3β may be a pharmacological target to inhibit testosterone-induced cardiac hypertrophy.
Vasodilation, a well-described event associated with testosterone, seems to be, at least in part, regulated by AR
activation. Hydrogen sulphide (H2S) is considered a prominent endothelium-derived hyperpolarizing factor that in-
duces vasodilation via TRPV4 and large-conductance Ca2+ -activated K channels [56]. Testosterone stimulation in
thoracic aorta frommaleWistar rat results in a concurrent increase in the production ofH2S, and associated vasodila-
tion, which is AR-dependent [57–59]. Interestingly high levels of H2S inhibit AR binding in human prostate cancer
cells, suggesting a tissue-specific feedback loop, whichmay offer future treatment options for castration resistant pro-
state cancer [60]. Moreover, chronic stimulation with androgens (24 h) seems to have a direct effect in endothelial
cells. DHT increases the levels of vascular endothelial growth factor and improves the proliferative, migratory and
adhesive abilities of endothelial progenitor cells, events regulated by the RhoA/ROCK pathway [4].
Androgens also have a direct effect on Ang II type-2 receptor (AT2R) expression. In aortas isolated from male
rats, AT2R mRNA and protein expression levels are lower than in females. The elevated level of AT2R mRNA and
protein expression in endothelium-intact aorta from female rats can be reversed by DHT administration, an effect
attenuated through co-administration of AR antagonist and not observed in the presence of an ERK1/2 inhibitor.
Interestingly, DHT therapy in females did not alter AT2R expression in endothelium-denuded aorta. On the other
hand, castration of male rats significantly elevated AT2RmRNA and protein expression, suggesting that independent
of the sex, testosterone via AR has a direct effect on expression of the Ang II receptor [61].
Genomic action of the AR in erectile function
ED provides another example of the clinical significance of the genomic effects of androgens. ED is considered a com-
plex neurovascular phenomenon and hypogonadism is the most common risk factor for this, leading to insufficient
arterial blood flow to the penis [62–65]. Castrated rats exhibit impaired erectile function and internal pudendal arter-
ies from castrated animals demonstrate impairment in vasoconstrictor and vasodilator function, which is associated
c© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons
Attribution Licence 4.0 (CC BY-NC-ND).
1407
Clinical Science (2017) 131 1405–1418
DOI: 10.1042/CS20170090
Table 1 Summary of the genomic effects of androgens
Androgen Cell/Tissue Effect Reference
Testosterone
DHT
VSMC mouse ↑ AR expression
↑ Calcium deposition
↑ mRNA expression Alpl
Zhu et al. (2016)
[46]
Testosterone Human aortic smooth muscle cells Phosphorylation of PI3K/Akt
Transactivation Gas6
Son et al. (2010)
[49]
Testosterone VSMC mouse ↓ Senescence
↓ Expression MMP-2
↓ Ang II-induced collagen
synthesis
Chen et al. (2016)
[50]
Testosterone α-galactosidase A knockout mice ↑ AR expression and mRNA
↓ Akt phosphorylation with
castration
Shen et al. (2015)
[52]
Testosterone ARKO mice ↓ ERK 1/2 and ERK 5 Ikeda et al. (2005)
[53]
Testosterone Cardiomyocytes Phosphorylation GSK-3β inhibitory
site (Ser9)
↑ Intracellular calcium
↑ Calcineurin and NFAT
↑ Cell size
Duran et al. (2016)
[55]
Testosterone Thoracic aorta rat ↑ H2S production
↑ Vasodilation
Bucci et al. (2009)
[57]
Brancaleone et al. (2015)
[58]
Mustafa et al. (2011)
[59]
DHT Endothelial progenitor cells ↑ VEGF
↑ Proliferation, migration and
adhesion of cells
Zhang et al. (2016)
[4]
DHT Rat aorta ↓ AT2R mRNA and protein
expression
↑ ERK 1/2 activation
Mishra et al. (2016)
[61]
with hypotrophic vascular remodelling, decreased neuronal nitric oxide synthase (nNOS) and α-actin expression and
increased collagen expression, p38 mitogen-activated protein kinases (p38) phosphorylation and caspase 3 cleavage
[66]. In penile tissue, AR expression reduces in an age-dependent manner and also in a testosterone dose-dependent
manner. The reduced AR expression may therefore play a role in the ED vascular phenotype [67].
Table 1 and Figure 1 summarise the genomic actions of androgens on the vasculature [4,46,49,50,52,53,55–59,61].
Non-DNA binding-dependent actions of the androgens
In the past, interactions with a nuclear sex hormone receptor followed by transcription factor activity were implicated
as the principal molecular mechanism responsible for androgen activity. However, there is increasing evidence that
androgens can also act via mechanisms independent of the ligand-dependent transactivation function of nuclear
receptors [68]. This is known as ‘non-genomic’ signalling, which typically occurs within a short time frame [69].
To be considered a non-genomic response, the androgen-induced response must occur in a time frame not long
enough to allow gene transcription, normally seconds to minutes. The response should be observed even when the
androgen is conjugated to molecules such as bovine serum albumin (BSA) that prevent it from entering into the
cytoplasm. A third criterion requires that the non-genomic response should not be blunted by inhibitors of tran-
scription and does not require a functional nucleus or transcription/translationmachinery activation [39,69,70]. The
non genomic actions of androgens in the vasculature are summarised in Figure 2 and Table 2.
Calcium mobilization and vascular function
The most robust evidence that androgens induce cellular effects through non-genomic signalling is the rapid rise of
intracellular calcium concentration [71,72]. Hypogonadism is associated with an increased risk of osteopenia and
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Figure 1. DNA binding-dependent signalling induced by androgens
(1) The genomic AR signalling involves androgen crossing the plasmamembrane, entering the cytoplasm, dissociation of chaperone proteins
and binding to the AR. (2) Testosterone induced-ROS generation is followed by an increase in Nox1 and Nox4 mRNA levels and p47phox
protein expression. (3) Gas6 signalling induced by testosterone is mediated by phosphorylation of the PI3K/Akt pathway, and an increase of
anti-apoptotic Bcl2 family proteins. (4) Hypertrophy induced by testosterone involves recruitment of NFAT through calcineurin activation and
GSK-3β inhibition. (5) Testosterone down-regulates the AT2R receptor via AR-mediated ERK1/2 activation. (6) Hypogonadism is shown to
decrease nNOS and α-actin expression and increase p38 phosphorylation and caspase 3 cleavage. (7) Testosterone stimulation results in a
concurrent increase in the production of H2S, and consequently vasodilation via TRPV4 and large-conductance Ca2+ -activated K-channels.
osteoporosis, an effect normalized by testosterone replacement [73]. In male rat osteoblasts, low concentrations of
testosterone, 10 pm/l–1 nM/l increase cytosolic free calcium andmembrane phospholipidmetabolism in a very rapid
time (5–60 s), an effect followed by an increase in the cellular content of inositol 1,4,5-trisphosphate (IP3) and diacyl-
glycerol (DAG) formation, events not observed in female rat osteoclasts, which suggest that the rapid effect induced
by testosterone is sex dependent. Interestingly, androgen-induced increases in intracellular levels of calcium are also
observed in testosterone conjugated with BSA, suggesting a response that involves membrane embedded or associ-
ated receptors or binding proteins [74]. Androgens/AR can also activate L-type calcium channels, which increase the
intracellular levels of calcium, activate protein kinase C (PKC) and via calmodulin activate protein kinase A (PKA)
and MAPK pathways [39].
Non-genomic Ca2+ mobilization by androgens was also observed in murine macrophages. In macro-
phages, testosterone increases intracellular levels of Ca2+ [75]. During this process, androgen interacts with
membrane-associated AR, modulates G-protein activity and subsequently activates phospholipase C (PLC). This res-
ults in the rapid release of intracellular calcium stores from the sarcoplasmic reticulum and consequently activation
of the RAS/MEK/ERK MAPK pathway [39]. Likewise through activation of plasma membrane AR associated with
GPCR signalling in cardiac myocytes, stimulation with testosterone induces the release of Ca2+ from internal stores,
such as endoplasmic reticulum and mitochondria [39,41].
Acute testosterone-induced non-genomic vasodilatation is mediated in part via endothelium-derived NO [76,77].
Aortic endothelial cells (AEC) stimulated with testosterone or non-permeable testosterone-BSA at physiological
concentrations (1–100 nm) present rapid (15–30 min) increases in NO level in AEC; testosterone also induces en-
dothelial nitric oxide synthase (eNOS) phosphorylation (Ser1177) without changing the total protein level. Activation
of eNOS occurs via PI3K, caveolin-1 and c-proto-oncogene tyrosine-protein kinase (Src) binding to AR and con-
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Figure 2. Non-DNA binding-dependent signalling induced by androgens
(1) Testosterone via rapid response activates PLC, IP3 and DAG and initiates intracellular calcium release and PKC activation. (2) Via binding
to GPRC6A, testosterone leads to ERK phosphorylation by mechanisms involving PI3K, PKC and Src. (3) GPRC6A mediates the non-ge-
nomic effects of testosterone on intracellular calcium mobilization and H2O2 through Duox1. (4) ZIP9 activation induced by testosterone
is involved in testosterone induced ERK1/2, CREB and pATF-1 phosphorylation. (5) Via interaction with AR, androgens activate L-type
calcium channels, which increase the intracellular levels of calcium, activate PKC, and via calmodulin activate PKA and MAPK pathways.
(6) Activation of PI3k/Akt signalling and the direct interaction of AR with p85α/c-Src/caveolin1 are involved in testosterone-induced eNOS
phosphorylation. (7) Testosterone increases mitochondrial-ROS generation and procaspase-8 and -3 activation in VSMC, an effect followed
by reduction of O2 consumption, increased expression of death receptors and apoptosis. (8) Rapid generation of ROS induced by testoster-
one involves NAPH oxidase activation. (9) Androgen binding to TRPM8 is followed by an increase in TRPM8-induced increase in intracellular
levels of Ca2+ .
sequently phosphorylation of AKT. AR and s-Src mediate testosterone-induced rapid eNOS phosphorylation, since
pre-treatment with nilutamide or PP2, an AR and s-Src antagonist respectively, abolishes the testosterone responses.
Transcriptional inhibitor, actinomycin D does not affect testosterone-induced increase in NO, which excludes the
classical genomic actions [78,79]. Anastrozole or other oestrogen receptor antagonists do not interfere in NO gener-
ation induced by testosterone, suggesting that this is not an event associated with the aromatization of testosterone
to oestradiol [80]. In addition, testosterone at physiological concentrations inhibits PGF2α-induced Ca2+ fluxes by
a non-genomic mechanism in VSMC [81], which may contribute to testosterone-induced vasodilatation.
Vasodilatation not associated with DNA-binding induced by testosterone is also observed in humans. A recent
paper demonstrated that administration of transdermal testosterone in men with hypogonadism and severe hy-
potestosteronaemia causes an acute vasodilation and improves arterial stiffness by non-genomic mechanisms, al-
though interestingly, the improvement is also evident after 96 h of treatment, which would suggest a combination of
genomic and non-genomic effects to reach the same response [82].
Themolecularmechanisms underlying non-genomic actions include not only the translocation of theAR to the cell
surface membrane [25] as many types of cells that demonstrate a rapid androgen response do not express the classic
nuclear AR or are not blocked by AR antagonists, suggesting that in addition to the traditional AR, other proteins
are capable of binding androgens and activating signal transduction cascades [39]. In addition to AR, androgens
can also bind to lipids of the plasmatic membrane, promoting direct modification of ion channels [69], activation of
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Table 2 Summary of non-genomic effects of androgens on vascular tissue
Androgen Cell/Tissue Effect Reference







Foradori et al. (2008)
[39]
Testosterone Cardiac myocytes ↑ Release Ca2+ from endoplasmic
reticulum and mitochondria
Bennett et al. (2010)
[41]
Foradori et al. (2008)
[39]
Testosterone Male rat osteoblasts ↑ Cytosolic free calcium
↑ IP3 and DAG formation
Lieberherr et al. (1994)
[74]
Testosterone AEC Rapid ↑ NO
eNOS phosphorylation
PI3K, cavceolin-1 and c-Src
binding to AR
AKT phosphorylation
Son et al. (2010)
[49]
Yu et al. (2010)
[79]
Testosterone VSMC Inhibits PGF2α induced Ca2+
inﬂux
Ma et al. (2009)
[81]





Testosterone Prostate cancer cells TRPM-8 induced ↑ intracellular
Ca2+






↑ ERK activity Pi et al. (2010)
[128]
Testosterone VSMC rats ROS generation
↑ Nox1 and Nox4 mRNA
↑p47phox protein
VSMC migration
Chignalia et al. (2012)
[129]








Ko et al. (2014)
[96]
Testosterone 93RS2 Sertoli cells ERK1/2 phosphorylation
CREB phosphorylation
ATF-1 phosphorylation
Bulldan et al. (2016)
[86]
Testosterone Prostate and breast
cancer cell lines




↑ Pro-apoptotic Bax, caspase 3,
cytochrome c proteins
Apoptosis
Thomas et al. (2014)
[87]
Testosterone VSMC Mitochondrial ROS generation
Procaspase-8 and -3 activation
↓ O2 consumption
Apoptosis
Lopes et al. (2014)
[14]
GPRC6A [83–85] and interaction with ZIP9, a Zn2+ transporter from the family of the zinc-regulated transporter
(ZRT), iron-regulated transporter (IRT)-like proteins [86,87].
An important example of testosterone-induced signal transduction cascades not dependent of binding to AR is
the androgen binding to transient receptor potential cation channel subfamily Mmember 8 (TRPM8). TRPM8 plays
an important role in the pathophysiology of prostate cancer and is considered an ionotropic testosterone receptor
[88]. In prostate cancer LNCaP cells, TRPM8 acts as a Ca2+ -permeable channel and is expressed in the endoplasmic
reticulum and plasma membrane. siRNA or inhibition of TRPM8 is associated with apoptosis of LNCaP cells. In-
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creased levels of testosterone are followed by a greater TRPM8-induced increase in intracellular levels of Ca2+ [89].
Picomolar concentrations of testosterone elicited Ca2+ responses and channel currents, and those were inhibited in
the presence of a TRPM8 antagonist [90]. Considering that TRPM8 has an important role in cell survival and that
TRPM8 is modulated by androgens, it might be predicted that anti-androgen therapy decreases the percentage of
LNCaP viable cells via reduction of TRPM8.
GPRC6A is expressed in many tissues including bone marrow stromal cells, monocytes, prostate cancer cells,
skeletal muscle cells, vascular smooth muscle and endothelial cells and Leydig cells [83,91]. Synthetic androgen
R1881 and testosterone alone or conjugated with BSA, in a calcium dependent manner, rapidly stimulate ERK activ-
ity in HEK-293 cells (which lack both the AR and GPRC6A receptor) transfected with GPRC6A, but not in the
non-transfected HEK-293 controls. This effect is reversed by an MAPK inhibitor, PI3K inhibitor, Src inhibitor and
PKC inhibitor; flutamide has no effect on testosterone-stimulated GPRC6A activation of p-ERK. Interestingly, R1881
does not stimulate ARE-luciferase activity in HEK-293 cells expressing only GPRC6A, but does stimulate HEK-293
cells transfected with AR, suggesting activation of nuclear receptor signalling. In vivo, testosterone-induced ERK
phosphorylation in the bone marrow and testes is markedly attenuated in GPRC6A− /− mice, demonstrating that
GPRC6A is a non-classical receptor for which androgens induce ERK activation both in vitro and in vivo [92].
ROS generation and apoptosis
Testosterone has been implicated in hypertension-induced vascular remodelling, an event associatedwith ROS gener-
ation. ROShave been recognized as importantmessengers in cell signalling [93]. Testosterone induces ROS generation
in VSMC isolated from normotensive (Wistar Kyoto, WKY) and hypertensive (spontaneously hypertensive rat, SHR)
rats, an effect followed by an increase in nicotinamide adenine dinucleotide phosphate oxidase (Nox)1 and Nox4
mRNA levels and p47phox protein expression and VSMC migration. Curiously, rapid ROS generation in SHRSP is
not inhibited by flutamide or actinomycin D, indicating a non-genomic effect. The complexity of the assessment of
the genomic and non-genomic effects of testosterone in the vasculature is highlighted in this study as testosterone
augmented ROS formation after 2 h was blocked by flutamide and actinomycin D, suggesting a genomic pathway and
demonstrating that testosterone has the potential to act in multiple different ways in the same cells [94].
In addition to Nox1 andNox4, the aforementioned isoforms, the Nox family includes five others isoenzymes (gp91
phox, renamedNox2, Nox3, Nox5, Duox1 andDuox2) [95]. In epidermal keratinocytes, testosterone stimulation res-
ults in rapid and transient Ca2+ mobilization from the endoplasmic reticulum within 1 min, an effect reduced by
transfection of GPRC6A siRNA and followed by an increase in H2O2 generation. Testosterone-induced H2O2 gener-
ation is not reverted by flutamide but not observed in the presence of DPI, an Nox inhibitor. ROS generation is not
observed in Duox1-silenced or GPRC6A-silenced keratinocytes. Stimulation of keratinocytes with testosterone res-
ults in decreased mitochondrial membrane potential and apoptosis, an event also regulated by GPRC6A-dependent
Ca2+ mobilization. Together, these results suggest that GPRC6A-dependent Ca2+ mobilization stimulates the activ-
ity of Duox1, leading to ROS generation and apoptosis [96]. The pro-apoptotic effect of testosterone is also observed
in VSMC. Testosterone increases mitochondrial-ROS generation and procaspase-8 and -3 activation in VSMC, an
effect followed by reduction of O2 consumption, increased expression of death receptors and apoptosis [14]. It has
not yet been investigated whether GPRC6A or Duox-1 are also involved in testosterone-induced ROS generation
and apoptosis in VSMC, which would be a new mechanism by which testosterone influences vascular function and
may play a role in cardiovascular diseases. Together, the previous results suggest that it is possible that the effects in
the vascular system induced by androgens are mediated by signalling cascades activated by oxidative stress, which
highlights ROS as an important target particularly in patients with augmented testosterone levels.
It has been demonstrated that GPRC6A is not only an androgen target but also an androgen regulator. GPRC6A
knockout mice display feminization of the external genitals, characterized by reduction in genitoanal distance as well
as testicular size, which is followed by reduced levels of testosterone, but no difference in AR levels. Interestingly,
oestradiol concentrations are significantly higher in male GPRC6A− /− mice compared with wild-type littermates,
an event associated with the increase in aromatase expression, a protein responsible for catalysing the oestrogen
biosynthesis from androgens. GPRC6A is highly expressed in the kidney [97] and GPRC6A− /− mice present an
increase in urinary calcium and phosphate excretion and also excretion of β2-microglobulin. In addition, liver from
GPRC6A− /− mice exhibits histologicalmarkers of hepatic steatosis [98]. Considering thatGPRC6A is involved in the
rapid effects of testosterone and that GPRC6A hasmultiple functions, it is possible thatmany important non-genomic
effects induced by testosterone are still unknown.
In addition toGPRC6A, non-DNAbinding-dependent actions of testosterone can also be associatedwith androgen
binding to ZIP9, a membrane-integrated receptor [86]. In this case, ZIP9 would perform dual functions as a mem-
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braneAR and zinc transporter. In 93RS2 Sertoli cells, a cell line that does not expressAR, testosterone (10 nM) induces
ERK1/2 phosphorylation. Similar effects were also observed in cAMP response element-binding protein (CREB) and
activating transcription factor 1 (ATF-1) phosphorylation, effects suppressed by ZIP9 siRNA, indicating that ZIP9 is
involved in the testosterone-induced signalling pathway [86].
As previously mentioned, testosterone induces apoptosis in different types of cells, including VSMC [14,89,96],
an event where ZIP9 seems to play an important role. In cancer cells, testosterone stimulation induces activation of
G proteins, up-regulation of JNK gene expression, ERK phosphorylation and increased expression of pro-apoptotic
Bax, caspase 3 and cytochrome c proteins, culminating in apoptosis. Transfection of ZIP9 siRNA is accompanied by
a complete loss of testosterone-induced apoptosis [87]. It has not yet been investigated whether this novel steroid
signalling pathway is initiated through the zinc transporter ZIP9 in VSMC also.
Implications for androgen therapy in cardiovascular disease
The use of androgens leads to effects that range from protective to deleterious [99], resulting in an ongoing debate
regarding the clinical benefits and long-term risks of testosterone therapy. As previously mentioned, genomic and
non-genomic effects of testosterone can result in different responses, which may help us to understand the divergent
outcomes of testosterone therapy in the cardiovascular system.
Men with low testosterone have a high prevalence of cardiovascular disease and metabolic syndrome [100–102]
and testosterone therapy in these individuals has been associated with reduced obesity, fat mass, waist circumference
andmortality as well as improved glycaemic control and overall cardiometabolic status compared with placebo [103].
On the other hand, testosterone supplements are known to increase haematocrit levels and reduceHDL (high-density
lipoprotein) cholesterol levels and have been implicated in cases of cardiovascularmorbidity andmortality [104]. Des-
pite this, a systematic review and meta-analysis evaluating the cardiovascular effects of testosterone supplementation
in 3016 men who were supplemented with testosterone and 2448 placebo-treated men found no causal role between
testosterone supplementation and cardiovascular events [105]. The results are so divergent that even the route of
administration of testosterone may be associated with differing cardiovascular risk [106].
A prospective study with 11,606men, aged 40–79 years, found that testosterone baseline levels are inversely related
tomortality due to all causes, cardiovascular diseases and cancer [34]. All-causemortality is increased in hypogonadal
men with Type 2 diabetes and testosterone therapy reduces mortality to 8.4% compared with 19.2% in the untreated
group [107]. Corroborating these results, a large multi-centre, randomized, double-blind, placebo-controlled study
undertaken in eight European countries in men with Type 2 diabetes and/or the metabolic syndrome showed that
testosterone replacement therapy (TRT) improves cardiovascular risk factors inmen, including body fat composition,
cholesterol, insulin resistance and sexual function [28].
In humans, low testosterone levels are associated with endothelial dysfunction [108], which can be reverted by
testosterone therapy. The vascular function of male patients as examined by the vasomotor function of the brachial
artery and intima-media thickness of the carotid artery demonstrated that low levels of testosterone are associated
with endothelial dysfunction, independent of bodymass index, presence of diabetes, hyperlipidaemia or hypertension
and age [109].
However, protective effects in the heart are also observed with testosterone therapy. Haemodynamic parameters in
patients and animalmodels of heart failure are improved by testosterone therapy,mainly via increased coronary blood
flow through vasodilation, reduction in peripheral vascular resistance and via direct effects in the cardiac tissue such
as inhibition of cardiac cAMPphosphodiesterases [110,111]. These potentially protective effects have been considered
in a recent clinical study by Cheetham et al. [112], which compared a group of 8808 men who had received TRT and
35,527 men who had never received TRT. The primary outcome of the study was an amalgamation of incidence
of acute myocardial infarction, coronary revascularization, unstable angina, stroke, transient ischaemic attack and
sudden cardiac death. The rates of cardiovascular disease, as determined by this amalgamation of information were
23.9 in the no-TRT group versus 16.9 per 1000 in the TRT groups, demonstrating that testosterone supplementation
in men with androgen deficiency results in a reduced risk of adverse cardiovascular outcomes [112].
Low-density lipoprotein, total cholesterol and triglycerides are reduced by testosterone therapy; in addition,
testosterone replacement increases high-density lipoprotein (HDL) and inhibits fatty streak formation, suggesting
a protective effect against atherosclerosis [113–115]. Similarly, some studies including 4-year follow-up study found
that the degree of atherosclerosis progression is inversely associated with testosterone levels [116,117].
Despite the results mentioned above, androgens may have a deleterious influence in the cardiovascular system
via an increase in blood pressure and renal dysfunction. Increased renal vascular resistance and ROS generation in
male elderly SHR are prevented by orchiectomy [118,119]. Likewise infusion of DHT in animals is associated with an
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increase in blood pressure, increase in sodium and water reabsorption and also ROS generation, an effect reversed by
6 weeks of treatment with the SOD mimetic tempol [120,121]. As mentioned before testosterone also induces ROS
generation and apoptosis of VSMC [14], increases the level of important sources of ROS and NADPH oxidase [94]
and also decreases the expression of antioxidant enzymes [122], which suggests that detrimental effects induced by
testosterone can involve an imbalance between pro- and-antioxidant systems, leading to oxidative stress.
Deleterious effects of testosterone are also observed in females. Increased testosterone levels in women with
polycystic ovary syndrome are associated with cardiovascular and metabolic disease. These patients have a
2-fold-increased risk for arterial disease independent of bodymass index, hypertension and diabetes status [123,124].
In addition, women with cardiovascular disease have higher levels of free androgen compared with controls [125].
Many studies have demonstrated that an equilibrium in testosterone levels is essential for the appropriate function
of many signalling pathways in different organs and tissues (Figures 1 and 2). However, the protective/deleterious
effect induced by testosterone therapy remains controversial. Differential effects are possibly due to activation of
distinct sets of signalling pathways. The EuropeanMale Ageing Study (EMAS) is a prospective multi-centre approach
that followed up 1887 men over a median of 4.3 years [126]. They investigated the AR gene exon 1 CAG repeat
length of these men, as this may be associated with androgen action [127]. In individuals with longer repeats, an
intact gonadal axis compensated for this adverse genetic background, meaning that affected individuals with normal
hormone biochemistry did not have an increased risk of cardiovascular or other medical conditions, suggesting that
the effect of testosterone may be mediated through non-genomic actions in these individuals [126]. It is clear that the
improved understanding of genomic and non-genomic effects of testosterone will therefore lead to the potential for
development of novel therapeutic targets for patients with cardiovascular disease.
Conclusions
It is clear that genomic and non-genomic effects induced by androgens have implications for the development of
cardiovascular disease. These effects range from protective, such as reduced fat mass, to deleterious including activa-
tion of pro-apoptotic and pro-oxidant signalling pathways. Accordingly, a consensus has yet to be reached regarding
the effects of testosterone on the cardiovascular system. Considering that even testosterone-induced genomic and
non-genomic responses could lead to divergent outcomes such as rapid improvement of vascular function via release
of NO and hydrogen sulphide or chronic vascular dysfunction associated with calcification, the improved under-
standing of themechanisms bywhich testosterone induces acute or chronic responses could be crucial to comprehend
the discrepant outcomes induced by androgens. Given that cardiovascular disease remains a major cause of human
death, particularly in males and post-menopausal women, further translational research in the field of genomic and
non-genomic effects of testosterone may lead to novel therapeutic targets for patients in the future.
Clinical perspectives
• Androgens have many extragonadal effects, including regulation of the cardiovascular system.
• Via activation of genomic and non-genomic signalling pathways, androgens can lead to divergent
outcomes.
• In the vascular system, androgens have the potential to cause NO release, Ca2+ mobilization, vas-
cular apoptosis, hypertrophy, calcification, senescence and ROS generation.
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